News
Datroway is used to treat an advanced form of non-small cell lung cancer in adults who had received prior treatment.
The drug was approved to treat patients who have already received chemotherapy under an accelerated approval process after a Phase 2 trial. The approval was also supported by data from a Phase 3 trial ...
AstraZeneca (AZ) and Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been granted accelerated approval by the US Food and Drug Administration (FDA) to treat a subset of non-small cell lung ...
Datroway is a targeted trophoblast cell surface antigen 2 (TROP2)-directed DXd antibody drug conjugate (ADC), developed using Daiichi Sankyo's DXd ADC Technology.
AstraZeneca and Daiichi Sankyo entered into a global collaboration to jointly develop and commercialise Enhertu in March 2019 and Datroway in July 2020, except in Japan where Daiichi Sankyo maintains ...
Like many other major pharmaceutical companies, AstraZeneca is facing a series of patent cliffs for key treatments in its ...
AstraZeneca and Daiichi Sankyo have earned their second FDA approval for Datroway, scoring a nod for the drug to treat EGFR-mutated non-small cell lung cancer.
AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat a type of lung cancer, marking the first approval of the therapy in this ...
FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response rate and a $45 million milestone due.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results